Ocugen Taps Veteran Gene Therapy Executive as CFO Amid Key Regulatory Milestones
Event summary
- Ocugen appoints Rita Johnson-Greene as CFO, effective February 9, 2026.
- Johnson-Greene brings 20+ years of healthcare experience, including roles at ARM, Genetix Biotherapeutics, and Spark Therapeutics.
- Ocugen plans to submit its first of three Biologics License Applications (BLAs) in 2026.
- Johnson-Greene holds an MBA in Finance and Strategic Management from The Wharton School.
The big picture
Ocugen's appointment of Rita Johnson-Greene as CFO underscores its focus on strengthening leadership ahead of critical regulatory milestones. The move comes as the company prepares to submit its first BLA, a pivotal step in its efforts to address unmet medical needs in blindness diseases. Johnson-Greene's extensive background in gene therapy commercialization and operations positions her to drive efficiency and success in a highly competitive and regulated industry.
What we're watching
- Regulatory Execution
- Whether Ocugen can successfully navigate the BLA submission process and secure approvals for its gene therapy candidates.
- Strategic Leadership
- How Johnson-Greene's experience in scaling commercial operations will impact Ocugen's ability to bring its therapies to market.
- Market Positioning
- The pace at which Ocugen can differentiate itself in the competitive gene therapy space, particularly for blindness diseases.
Related topics